September 9, 2021

Q&As with Industry Leaders


Anki Magnusson, Staff Research Engineer, Protein and Viral Production, Cytiva
Åsa Hagner-McWhirter, PhD, Senior Scientist, Bioprocess Applications R&D, Cytiva

Anki Magnusson, Staff Research Engineer, Protein and Viral Production, Cytiva
Åsa Hagner-McWhirter, PhD, Senior Scientist, Bioprocess Applications R&D, Cytiva

James Blackwell, President, Windshire Group, LLC  

James Blackwell, President, Windshire Group, LLC

Steven Lynn, Executive Vice-President, Pharmaceuticals, Regulatory Compliance Associates 

Peter Guterstam, PhD, Product Manager of Next Generation Resins & Technologies at Cytiva
 
Peggy Lio, Senior Director of Global Cell Culture Services at Cytiva

Dr. Tobias Hahn, co-founder and CEO of GoSilico

Next Generation Process Chromatography
Dr. Oliver Hardick, Business Leader in the BioProcess group at Cytiva

Tools and Processes for Mature and Emerging Therapies
Rita Peters, Editorial Director of BioPharm International   
Dr. Mats Lundgren, Customer Applications Director at Cytiva

Eric Langer, President and Managing Partner at BioPlan Associates 

Dr. Neil Goss, Research and Development at CSL BioPlasma, Australia, and co-author of Production of Plasma Proteins for Therapeutic Use

Biopharma Says It Has an Evolution in New Technologies and Processes
Rita Peters, Editorial Director of BioPharm International  

Biopharmaceutical Market in Asia
Günter Jagschies, Strategic Customer Relations Leader, Cytiva
 
Techniques for Improving Process Development for Exosome-Derived Therapeutics
Aaron Noyes, Head of Downstream Processing at Codiak BioSciences 

John Curling, 3rd BioProcessing Asia Conference chair 

Jonathan Royce, Business Leader for Chromatography Resins, Cytiva

Hybrid Bioprocessing
Andrew Sinclair, President and Founder of BioPharm Services

Improvements in Protein A Chromatography
Glen Bolton, Scientific Director, Amgen

Speed and Flexibility Are Dual Goals for Biopharma Operations
Rita Peters, Editorial Director of BioPharm International 

Konstantin Konstantinov, VP Late Stage Process Development, Genzyme

Rita Peters, Editorial Director of BioPharm International   
 
Adopting Single-Use Systems
Parrish Galliher, Chief Technology Officer Upstream at Cytiva

The Evolution of the Role of CMOs in Bioprocessing

Eric Langer, President and Managing Partner at BioPlan Associates

3rd HTPD Conference
Phil Lester, Co-Organizer of the HTPD Conference

The Future of QbD, Part 1
Dr. Anurag Rathore, Professor, Department of Chemical Engineering, Indian Institute of Technology, Delhi

The Future of QbD, Part 2
Dr. Anurag Rathore, Professor, Department of Chemical Engineering, Indian Institute of Technology, Delhi 

Mechanistic Modeling: Does it Have a Future in Process Development?
Dr. Arne Staby, Fellow, Novo Nordisk

Continuous Chromatography: Trends, Definitions and Approaches
Dr. Karol Lacki, Customer Collaborations Leader, Cytiva

The Role of HIC in Biotech
Professor Alois Jungbauer, Department of Biotechnology, BOKU


Trends in Single-Use Technologies
Jeff Carter, Cytiva

Bioprocessing Trends and Technologies at INTERPHEX 2016
Rita Peters, Editorial Director of BioPharm International 

CMOs Embrace New Technology
Eric Langer, BioPlan Associates

Tags: process development; bioprocess development; Q&A